Olga Kim
Overview
Explore the profile of Olga Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
443
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Park K, Kim K, Seo E, Gemechu D, Kim O
IEEE Trans Neural Syst Rehabil Eng
. 2025 Mar;
33:975-983.
PMID: 40031625
Not only improving muscle strength but also improving muscle power and neuromuscular control are important factors in improving lower limb function. In this study, a multi-directional lower-limb training system for...
2.
Kim O, Sergi Z, Yu G, Yamamoto K, Quezado M, Abdullaev Z, et al.
Acta Neuropathol Commun
. 2024 Sep;
12(1):148.
PMID: 39256867
Malignant transformation (MT) is commonly seen in IDH-mutant gliomas. There has been a growing research interest in revealing its underlying mechanisms and intervening prior to MT at the early stages...
3.
Geisen V, Pantchev N, Zablotski Y, Kim O, Globokar Vrhovec M, Hartmann K, et al.
Animals (Basel)
. 2024 Aug;
14(16).
PMID: 39199902
Infections with () in cats seem to be rare. The study aimed to determine whether infections in cats are underestimated and to identify the risk factors for infection. Blood samples...
4.
Ma X, Botros A, Yun S, Park E, Kim O, Park S, et al.
Front Chem
. 2024 Jan;
11:1332816.
PMID: 38260043
No effective screening tools for ovarian cancer (OC) exist, making it one of the deadliest cancers among women. Considering that little is known about the detailed progression and metastasis mechanism...
5.
Ma X, Botros A, Yun S, Park E, Kim O, Chen R, et al.
bioRxiv
. 2023 Nov;
PMID: 37961688
No effective screening tools for ovarian cancer (OC) exist, making it one of the deadliest cancers among women. Considering little is known about the detailed progression and metastasis mechanism of...
6.
Pang Y, Li Q, Sergi Z, Yu G, Sang X, Kim O, et al.
bioRxiv
. 2023 Oct;
PMID: 37786680
Highlights: Zotiraciclib (ZTR), a CDK9 inhibitor, hinders IDH-mutant glioma growth and . ZTR halts cell cycle, disrupts respiration, and induces oxidative stress in IDH-mutant cells.ZTR unexpectedly inhibits PIM kinases, impacting...
7.
Kim O, Butler M, Sergi Z, Robey R, Zhang M, Chari R, et al.
Neurooncol Adv
. 2023 Sep;
5(1):vdad102.
PMID: 37706203
Background: Deletions or loss-of-function mutations in phosphatase and tensin homolog () are common in glioblastoma (GBM) and have been associated with defective DNA damage repair. Here we investigated whether PTEN...
8.
Merchant M, Raygada M, Pang Y, Quezado M, Raffeld M, Xi L, et al.
Front Oncol
. 2022 Aug;
12:954879.
PMID: 35982947
Most tumors, including brain tumors, are sporadic. However, a small subset of CNS tumors are associated with hereditary cancer conditions like Lynch Syndrome (LS). Here, we present a case of...
9.
Sah S, Yun S, Gaul D, Botros A, Park E, Kim O, et al.
Metabolites
. 2022 Jun;
12(6).
PMID: 35736465
The lack of effective screening strategies for high-grade serous carcinoma (HGSC), a subtype of ovarian cancer (OC) responsible for 70-80% of OC related deaths, emphasizes the need for new diagnostic...
10.
Sah S, Ma X, Botros A, Gaul D, Yun S, Park E, et al.
Cancers (Basel)
. 2022 May;
14(9).
PMID: 35565391
The dismally low survival rate of ovarian cancer patients diagnosed with high-grade serous carcinoma (HGSC) emphasizes the lack of effective screening strategies. One major obstacle is the limited knowledge of...